Table 2.
Mean echocardiographic left ventricular Z score measurements after treatment, by year since treatment completion
| 0 years | 1 year | 2 years | 3 years | 4 years | 5 years | |
|---|---|---|---|---|---|---|
|
Total sample
| ||||||
| Fractional shortening | ||||||
| Doxorubicin | −1·35 (−1·97 to −0·74) | −1·30 (−1·75 to −0·85) | −1·22 (−1·63 to −0·80) | −1·11 (−1·55 to −0·67) | −0·98 (−1·45 to −0·50) | −0·82 (−1·31 to −0·33) |
| Doxorubicin plus dexrazoxane | −0·88 (−1·45 to −0·31) | −0·80 (−1·22 to −0·37) | −0·70 (−1·10 to −0·31) | −0·61 (−1·03 to −0·19) | −0·51 (−0·96 to −0·06) | −0·41 (−0·88 to 0·06) |
| p value* | 0·26 | 0·11 | 0·08 | 0·11 | 0·16 | 0·22 |
| Mass | ||||||
| Doxorubicin | −0·29 (−0·75 to 0·17) | −0·75 (−1·04 to −0·47) | −0·98 (−1·30 to −0·67) | −0·98 (−1·29 to −0·67) | −0·74 (−1·13 to −0·34) | −0·26 (−1·03 to 0·51) |
| Doxorubicin plus dexrazoxane | −0·87 (−1·29 to −0·44) | −0·98 (−1·26 to −0·70) | −1·02 (−1·34 to −0·70) | −0·97 (−1·29 to −0·66) | −0·86 (−1·24 to −0·47) | −0·66 (−1·43 to 0·10) |
| p value* | 0·07 | 0·27 | 0·89 | 0·98 | 0·67 | 0·47 |
| End-diastolic dimension | ||||||
| Doxorubicin | 0·004 (−0·46 to 0·46) | 0·009 (−0·32 to 0·34) | 0·03 (−0·27 to 0·33) | 0·06 (−0·27 to 0·39) | 0·10 (−0·25 to 0·45) | 0·14 (−0·22 to 0·51) |
| Doxorubicin plus dexrazoxane | −0·49 (−0·92 to −0·06) | −0·48 (−0·80 to −0·16) | −0·44 (−0·74 to −0·14) | −0·37 (−0·69 to −0·05) | −0·27 (−0·62 to 0·07) | −0·15 (−0·51 to 0·21) |
| p value* | 0·12 | 0·04 | 0·03 | 0·07 | 0·14 | 0·26 |
| End-systolic dimension | ||||||
| Doxorubicin | 0·55 (0·11 to 0·99) | 0·56 (0·25 to 0·90) | 0·59 (0·29 to 0·89) | 0·59 (0·27 to 0·92) | 0·59 (0·24 to 0·93) | 0·57 (0·21 to 0·93) |
| Doxorubicin plus dexrazoxane | 0·004 (−0·41 to 0·41) | 0·01 (−0·31 to 0·33) | 0·03 (−0·27 to 0·33) | 0·06 (−0·26 to 0·37) | 0·10 (−0·24 to 0·44) | 0·15 (−0·20 to 0·51) |
| p value* | 0·07 | 0·01 | 0·0097 | 0·02 | 0·0455 | 0·10 |
| End-diastolic posterior wall thickness | ||||||
| Doxorubicin | −0·0001 (−0·44 to 0·44) | −0·35 (−0·64 to −0·06) | −0·65 (−0·90 to −0·39) | −0·89 (−1·18 to −0·61) | −1·09 (−1·40 to −0·77) | −1·23 (−1·56 to −0·90) |
| Doxorubicin plus dexrazoxane | −0·56 (−0·97 to −0·15) | −0·57 (−0·85 to −0·29) | −0·60 (−0·85 to −0·35) | −0·64 (−0·92 to −0·36) | −0·69 (−1·00 to −0·39) | −0·76 (−1·08 to −0·44) |
| p value* | 0·07 | 0·27 | 0·80 | 0·21 | 0·08 | 0·04 |
| End-diastolic thickness-to-dimension ratio | ||||||
| Doxorubicin | 0·13 (−0·36 to 0·62) | −0·21 (−0·55 to 0·12) | −0·50 (−0·80 to −0·21) | −0·74 (−1·07 to −0·42) | −0·93 (−1·29 to −0·58) | −1·07 (−1·44 to −0·70) |
| Doxorubicin plus dexrazoxane | −0·12 (−0·58 to 0·33) | −0·09 (−0·41 to 0·23) | −0·10 (−0·39 to 0·18) | −0·16 (−0·47 to 0·15) | −0·26 (−0·60 to 0·07) | −0·41 (−0·76 to −0·06) |
| p value* | 0·45 | 0·61 | 0·06 | 0·01 | 0·0069 | 0·0094 |
|
| ||||||
|
Girls
| ||||||
| Fractional shortening | ||||||
| Doxorubicin | −1·28 (−2·16 to −0·40) | −1·56 (−2·11 to −1·00) | −1·74 (−2·26 to −1·22) | −1·83 (−2·44 to −1·22) | −1·82 (−2·51 to −1·13) | −1·72 (−2·44 to –1·00) |
| Doxorubicin plus dexrazoxane | −0·34 (−1·23 to 0·56) | −0·41 (−1·01 to 0·20) | −0·46 (−0·96 to 0·03) | −0·50 (−1·02 to 0·01) | −0·53 (−1·11 to 0·04) | −0·55 (−1·15 to 0·07) |
| p value* | 0·14 | 0·0062 | 0·0007 | 0·0017 | 0·0057 | 0·01 |
| End-diastolic thickness-to-dimension ratio | ||||||
| Doxorubicin | −0·32 (−0·98 to 0·34) | −0·48 (−0·90 to −0·06) | −0·63 (−1·02 to −0·25) | −0·79 (−1·26 to −0·33) | −0·95 (−1·48 to −0·43) | −1·12 (−1·66 to −0·57) |
| Doxorubicin plus dexrazoxane | −0·19 (−0·86 to 0·49) | −0·01 (−0·47 to 0·44) | 0·09 (−0·28 to 0·47) | 0·14 (−0·26 to 0·53) | 0·11 (−0·32 to 0·55) | 0·03 (− −0·43 to 0·48) |
| p value* | 0·77 | 0·14 | 0·0099 | 0·0035 | 0·0024 | 0·0017 |
|
| ||||||
|
Boys
| ||||||
| Fractional shortening | ||||||
| Doxorubicin | −1·18 (−2·04 to −0·32) | −1·06 (−1·61 to −0·50) | −0·94 (−1·39 to −0·49) | −0·82 (−1·31 to −0·33) | −0·70 (−1·24 to −0·17) | −0·58 (−1·13 to −0·03) |
| Doxorubicin plus dexrazoxane | −1·22 (−1·96 to −0·48) | −1·21 (−1·69 to −0·73) | −1·15 (−1·59 to −0·72) | −1·04 (−1·54 to −0·55) | −0·89 (−1·44 to −0·34) | −0·68 (−1·25 to −0·11) |
| p value* | 0·94 | 0·68 | 0·50 | 0·53 | 0·63 | 0·81 |
| End-diastolic thickness-to-dimension ratio | ||||||
| Doxorubicin | 0·52 (−0·15 to 1·19) | 0·06 (−0·37 to 0·50) | −0·33 (−0·69 to 0·02) | −0·66 (−1·04 to −0·28) | −0·93 (−1·34 to −0·51) | −1·12 (−1·56 to −0·69) |
| Doxorubicin plus dexrazoxane | −0·17 (−0·76 to 0·41) | −0·27 (−0·65 to 0·11) | −0·39 (−0·73 to −0·05) | −0·54 (−0·93 to −0·15) | −0·72 (−1·15 to −0·29) | −0·93 (−1·38 to −0·48) |
| p value* | 0·12 | 0·26 | 0·82 | 0·67 | 0·51 | 0·54 |
Data are mean (95% CI).
*
p value is for comparison of the doxorubicin group with the doxorubicin plus dexrazoxane group. For regression equations used to calculate Z scores, see webappendix.